バイオコン・バイオロジクス、ヴィアトリス社バイオシミラー事業の統合を完了し世界最大手へ

This integration significantly bolsters India's position as a global biosimilars manufacturing and export hub, benefiting the broader APAC supply chain. For emerging Asian markets like Indonesia, Vietnam, and the Philippines, Biocon's expanded scale promises increased access to affordable cancer and autoimmune treatments, potentially impacting local healthcare budgets and competitive dynamics for regional pharmaceutical players. Monitor potential regulatory shifts in these markets to accommodate accelerated biosimilar approvals.